IP Commercializer PureTech Enters CAR-T With Vor BioPharma Start-Up

PureTech Health has moved into the hot area of CAR-T immuno-oncology by launching Vor BioPharma - but the IP commercializer isn't giving details on the start-up's novel chimeric antigen receptor T-cell therapy platform, or how it hopes to remove bottlenecks to the approach's use outside of B-cell cancers.

David Steinberg
David Steinberg, Executive Vice President of PureTech Health and Co-Founder of Vor BioPharma • Source: PureTech Health PLC

Boston, Mass.-based but UK-listed PureTech Health PLC says its Vor BioPharma start-up is advancing a novel approach to chimeric antigen receptor (CAR) T-cell therapy that has the potential to broaden the science's applicability and success rate in other cancers – but it's not willing to say exactly how it will do that.

Its platform technology has been licensed from the lab of Vor’s scientific co-founder, Siddhartha Mukherjee, who is assistant professor of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas